We estimate that the Aqua Maris line of products has the largest potential for this, since it has already proved to be an exceptionally successful and competitive brand, particularly on the CIS markets. In addition to Aqua Maris, our portfolio also includes a series of brands and products which offer an opportunity for international expansion.
JGL coordinates and upgrades its activities on a daily basis, in regards to business environment, organization, competence, technology and procedures, to create preconditions for meeting a wide range of customer needs with personalized, proactive services. We want to be the customer’s partner and their first solution in business.
We must find a good cost-investment balance, focused on small-scale but sustainable, long-term growth. Growth will be achieved through our own development and innovative solutions, primarily in the field of ophthalmology and ENT.
This primarily means development and production of sterile pharmaceutical forms in which we have the absolute edge. The balance of our portfolio lies in ensuring focus and in reducing the risk of dependence on only a few products on specific markets.